Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer.

Angeliki Andrikopoulou Michalis LiontosEfthymia SkafidaKonstantinos KoutsoukosKleoniki ApostolidouMaria KaparelouAngeliki RouvalisGaryfallia BletsaMeletios-Athanasios DimopoulosFlora Zagouri

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

We showed that the combination of pembrolizumab with bevacizumab and oral cyclophosphamide is an effective alternative in heavily pre-treated patients with ovarian cancer who have otherwise limited treatment options.

Keyphrases

low dose
high dose
advanced non small cell lung cancer
metastatic colorectal cancer
tyrosine kinase